Abstract
Genome-wide association studies (GWAS) of coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis (IPF) have identified genetic loci associated with both traits, suggesting possible shared biological mechanisms. Using updated GWAS of COVID-19 and IPF, we evaluated the genetic overlap between these two diseases and identified four genetic loci (including one novel) with likely shared causal variants between severe COVID-19 and IPF. Although there was a positive genetic correlation between COVID-19 and IPF, two of these four shared genetic loci had an opposite direction of effect. IPF-associated genetic variants related to telomere dysfunction and spindle assembly showed no association with COVID-19 phenotypes. Together, these results suggest there are both shared and distinct biological processes driving IPF and severe COVID-19 phenotypes.
Competing Interest Statement
G Jenkins is a trustee of Action for Pulmonary Fibrosis and reports personal fees from Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daewoong, Galapagos, Galecto, GlaxoSmithKline, Heptares, NuMedii, PatientMPower, Pliant, Promedior, Redx, Resolution Therapeutics, Roche, Veracyte and Vicore. L Wain holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1) and reports research funding from GSK and Orion and consultancy for Galapagos, outside of the submitted work.
Funding Statement
R Allen is an Action for Pulmonary Fibrosis Mike Bray Research Fellow. B Guillen-Guio is supported by Wellcome Trust grant 221680/Z/20/Z. L Wain holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This research used the SPECTRE High Performance Computing Facility at the University of Leicester.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study uses only openly available human data, which can be obtained from: https://github.com/genomicsITER/PFgenetics (IPF genome-wide summary statistics), https://www.covid19hg.org/results/r6/ (COVID-19 genome-wide summary statistics), https://gtexportal.org/home/datasets (lung eQTL data) and https://www.eqtlgen.org/index.html (blood eQTL data)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study used previously published publicly available data obtained from obtained from: https://github.com/genomicsITER/PFgenetics (IPF genome-wide summary statistics), https://www.covid19hg.org/results/r6/ (COVID-19 genome-wide summary statistics), https://gtexportal.org/home/datasets (lung eQTL data) and https://www.eqtlgen.org/index.html (blood eQTL data).
